BURLINGTON, Mass. and JERUSALEM, Jan. 10, 2024 BrainsWay Ltd. (NASDAQ & TASE: BWAY),’ a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, has announced strategic advancements aimed at enhancing the clinical application and market appeal of its Deep Transcranial Magnetic Stimulation (Deep TMS) technology. The company has initiated a prospective, randomized, controlled, multicenter trial to evaluate an accelerated version of its Deep TMS treatment for Major Depressive Disorder (MDD). Concurrently, BrainsWay will begin clinical evaluation of the innovative Rotational Field Deep TMS 360 technology in two new feasibility trials.
Accelerated Deep TMS for Depression
The upcoming multicenter trial aims to explore the efficacy of an accelerated Deep TMS protocol in the acute treatment phase for depression. Traditional Deep TMS treatments typically span several weeks, requiring daily sessions over a prolonged period. This new trial will assess whether a condensed treatment period can deliver comparable therapeutic outcomes more quickly, potentially increasing patient compliance and satisfaction.
Our goal with this accelerated Deep TMS trial is to make the treatment more accessible and appealing to both patients and healthcare providers,’ stated Yaacov Michlin, BrainsWay’s CEO. ’By shortening the acute treatment period, we believe that we can significantly expand the market opportunities for our Deep TMS technology, allowing more patients to benefit from this effective treatment method.’
The study will be conducted across several leading medical centers, leveraging BrainsWay’s unique H-Coil technology, which targets deeper and broader brain regions involved in depression. The trial will track a range of clinical outcomes, including the reduction of depressive symptoms and overall patient response rates.
Rotational Field Deep TMS 360 Technology
In addition to the accelerated Deep TMS trial, BrainsWay is pioneering the next generation of neurostimulation with its Rotational Field Deep TMS 360 technology. This innovative approach enhances the conventional TMS by rotating the magnetic field, ensuring a more comprehensive and uniform stimulation of the targeted brain regions. The technology is being evaluated in two new feasibility trials aimed at determining its safety, efficacy, and potential clinical applications.
We are excited to introduce the Rotational Field Deep TMS 360 technology as part of our ongoing commitment to technological innovation,’ added Michlin. ’This technique aims to optimize the therapeutic effects of Deep TMS, potentially improving patient outcomes across a variety of mental health disorders.’
The feasibility trials for Rotational Field Deep TMS 360 will involve patients with depression and other mental health conditions, seeking to establish proof-of-concept before broader clinical implementations.
Broadening Market Appeal
Through these innovative trials, BrainsWay continues to solidify its position as a frontrunner in noninvasive neurostimulation for mental health treatment. By aiming to shorten the acute treatment period for depression and exploring advanced stimulation techniques, the company is set to enhance the therapeutic efficacy and marketability of its Deep TMS solutions. These advancements not only have the potential to improve patient quality of life but also to open new market opportunities, reducing barriers for both providers and patients in accessing cutting-edge mental health treatments.
Looking Ahead
As BrainsWay moves forward with these clinical trials, the outcomes could pave the way for significant advancements in treating mental health disorders. Shortened treatment protocols and innovative technologies like the Rotational Field Deep TMS 360 hold the promise of improved patient engagement, outcomes, and broader adoption in the healthcare market.
The pioneering spirit of BrainsWay in enhancing and evolving its neurostimulation technologies underscores its dedication to providing effective, noninvasive treatment options for those suffering from mental health disorders, thus contributing to the overall advancement of mental health care.
Comments